Monday to Friday: 9am – 6pm | Saturday: 9am – 1pm | Sunday & PH: Closed
Medications & Oral Health
Can You Have a Tooth Extracted While on Bisphosphonates?
Medically Reviewed by
Dr Jonathan Liu · Principal Dentist and Founder · BDS (NUS) · SDC Reg. D21395J · 25+ Years of Clinical Experience
At a Glance
For most patients on oral bisphosphonates for osteoporosis, tooth extraction is possible. The estimated risk of MRONJ — a serious jaw complication — is under 0.1% at standard doses and durations under four years. The risk is meaningfully higher for patients receiving high-dose intravenous bisphosphonates or denosumab for cancer: estimated between 1% and 17%. Your dentist will assess your specific drug, dose, duration, and health history before deciding how to proceed.
For information on what dental clearance before starting bisphosphonate therapy involves, see our guide: Bisphosphonate therapy and dental clearance in Singapore.
Key Reference
Quick Facts
MRONJ Risk — Oral <4 Years
<0.1%
Standard oral osteoporosis dose — lower than annual road traffic injury risk in Singapore (SMJ 2018)
MRONJ Risk — Oral >4 Years
~0.21%
Risk rises modestly with longer duration — still low; does not prohibit extraction with careful technique
MRONJ Risk — IV Oncology Dose
1–17%
Zoledronic acid (Zometa) or denosumab (Xgeva) for cancer — oncology team involvement required
Most Common MRONJ Trigger
45–80%
Of cases associated with tooth extraction — careful technique and follow-up at 6–8 weeks are standard
Drug Holidays
Not routinely advised
AAOMS 2022 updated position — insufficient evidence; denosumab pause carries rebound fracture risk
Singapore Guideline
NUCOH 2025
Modified-Delphi Consensus — 29 clinical statements for dental management of antiresorptive patients
The Mechanism
What bisphosphonates do to bone
Bisphosphonates are prescribed to strengthen bone and reduce fracture risk. They work by suppressing osteoclasts — the cells responsible for breaking down and remodelling old bone. Commonly prescribed oral bisphosphonates for osteoporosis in Singapore include alendronate (Fosamax) and risedronate (Actonel). Intravenous formulations include zoledronic acid (Aclasta, given annually for osteoporosis; Zometa, given monthly for cancer). Denosumab (Prolia for osteoporosis; Xgeva for cancer) is a RANKL inhibitor — not a bisphosphonate, but with a comparable mechanism and risk profile.
Bisphosphonates bind tightly to bone mineral and persist in the skeleton for years after stopping. This pharmacological persistence is why their fracture-prevention benefit continues long-term — and also why a brief drug holiday before a dental procedure provides limited protection.
The Complication
MRONJ: the complication, explained plainly
MRONJ stands for medication-related osteonecrosis of the jaw. It is a condition in which bone in the jaw fails to heal after a wound — most commonly a tooth extraction — and exposed bone persists for eight weeks or more. It occurs because bisphosphonates suppress the bone remodelling process that normally closes a healing socket. The jawbones are uniquely vulnerable: they are continuously exposed to the oral bacterial environment through gum tissue and tooth roots.
MRONJ is not common at standard osteoporosis doses. The 2018 Singapore Medical Journal CME guideline notes the risk is lower than the annual probability of a road traffic injury in Singapore. At oncology doses, the risk is substantially higher and requires careful pre-procedural planning.
MRONJ staging — AAOMS 2022
At Risk
On antiresorptive therapy. No exposed bone. No symptoms. Requires monitoring at dental check-ups.
Stage 0
No exposed bone visible. Non-specific symptoms — pain, swelling, altered sensation. Requires close monitoring and oral hygiene support.
Stage 1
Exposed bone present. No pain. No clinical signs of infection. Conservative management with antiseptic rinse and monitoring.
Stage 2
Exposed bone with pain and clinical signs of infection. Requires antibiotic therapy and referral to oral and maxillofacial surgeon.
Stage 3
Exposed bone with pain, infection, and one or more of: pathological fracture, extra-oral fistula, osteolysis to inferior border. Requires specialist surgical management.
Key Signal
Bone visible in the socket not healing at the 8-week follow-up — contact your dentist immediately. Early referral to oral and maxillofacial surgery improves outcomes at every stage.
Risk Stratification
Risk by drug type
Not all bisphosphonates carry the same risk. The two primary variables are route of administration (oral versus intravenous) and the underlying condition being treated (osteoporosis versus active cancer with bone involvement). Corticosteroid co-prescription, diabetes, and smoking compound risk across all categories.
| Medication | Condition treated | Route | Estimated MRONJ risk |
|---|---|---|---|
| Alendronate (Fosamax) | Osteoporosis | Oral, daily or weekly | <0.1% (<4 yrs); ~0.21% (>4 yrs) |
| Risedronate (Actonel) | Osteoporosis | Oral | <0.1% |
| Zoledronic acid (Aclasta) | Osteoporosis | IV, annual infusion | ~0.017–0.35% |
| Denosumab (Prolia) | Osteoporosis | Subcutaneous, twice yearly | ~0.04–0.3% |
| Zoledronic acid (Zometa) | Cancer — bone metastases | IV, monthly | ~1–17% |
| Denosumab (Xgeva) | Cancer — bone metastases | Subcutaneous, monthly | Comparable to oncology-dose IV |
All figures are estimates from published clinical studies. Individual risk depends on duration, concurrent medications, and overall health.
Pre-Procedure Assessment
What your dentist needs to assess
Before proceeding with any extraction, your dentist will review the following. This assessment determines whether to proceed, how to proceed, and whether oncology team input is required.
- 1 Which bisphosphonate or antiresorptive you are taking and how it is administered (oral, IV, or subcutaneous injection)
- 2 Duration of use — risk rises modestly after four years of oral bisphosphonates
- 3 Whether you are also taking corticosteroids or receiving chemotherapy — both compound risk
- 4 Whether you have diabetes, anaemia, or any condition affecting wound healing
- 5 Whether you smoke — smoking is an established compounding risk factor for MRONJ
- 6 X-ray findings — bone quality, socket depth, proximity to vital structures
Patients on oral bisphosphonates for fewer than four years for osteoporosis, without other risk factors, can generally proceed. Patients on IV oncology-dose antiresorptives require oncology team input before any surgical dental procedure.
The Procedure
What happens at the extraction appointment
Where extraction is appropriate, your dentist will use a careful, tissue-preserving technique: minimal trauma to surrounding bone and gum, smooth bone edges at the socket, wound closure where possible, and antibiotic cover before and after the procedure.
A follow-up appointment at six to eight weeks is standard to confirm the socket has healed. If bone is visible in the socket beyond this point — particularly if persistent, painful, or associated with swelling — your dentist will refer you promptly to an oral and maxillofacial surgeon for assessment.
Visiting oral and maxillofacial surgeon at Dentalis: Complex extraction cases in patients on antiresorptive therapy are discussed with Dr Albert Lee Ming Hsien (MDS, FAMS, SDC D22238J), particularly where the risk profile is elevated or where the extraction site is anatomically sensitive.
Alternative to consider: root canal treatment
For teeth that might otherwise require removal, root canal treatment removes the source of infection while preserving the tooth root entirely — without a surgical wound in the bone. For borderline teeth in patients on antiresorptive therapy, this is often the preferred approach. Your dentist will advise whether this is clinically appropriate for your specific tooth.
Evidence Review
Drug holidays: what the evidence says
Stopping bisphosphonates before dental surgery — sometimes called a drug holiday — was previously recommended as a precautionary measure. The AAOMS 2022 position update no longer recommends this routinely for low-risk patients. A 2022 Cochrane systematic review found insufficient evidence that drug holidays reduce MRONJ incidence.
The limited benefit of a bisphosphonate holiday is partly pharmacological: the medication remains bound to bone for years after stopping. A brief pause does not meaningfully reduce bone concentrations or restore normal osteoclast activity within a clinically useful window.
Important: denosumab (Prolia / Xgeva)
Do not stop denosumab without consulting your prescribing physician. Missing a dose without a planned transition to bisphosphonate therapy can cause rapid bone loss and vertebral fractures within months of a missed injection.
The NUCOH Modified-Delphi Consensus 2025 and ACE 2025 Osteoporosis Guideline both support continuing antiresorptive therapy through dental procedures in most cases, with any modification to the treatment plan decided jointly between the prescribing physician and the dentist.
"Most patients on oral bisphosphonates for osteoporosis can proceed with tooth extraction safely. The risk of MRONJ at standard doses is genuinely low — and it should not prevent necessary dental treatment. What matters is a thorough assessment of the medication history, careful technique, and follow-up at six to eight weeks to confirm the socket has healed. For patients on IV oncology-dose antiresorptives, we work closely with the oncology team before proceeding with anything surgical."
Dr Jonathan Liu · Principal Dentist and Founder · BDS (NUS) · SDC Reg. D21395J · 25+ Years
Common Questions
Frequently asked questions
No. Three years of oral alendronate for osteoporosis places you in the low-risk category — MRONJ incidence is estimated under 0.1% at this duration. Your dentist will confirm your full picture at assessment and apply careful extraction technique. Follow-up at eight weeks to confirm healing is standard.
Denosumab (Prolia for osteoporosis) is not a bisphosphonate but has a comparable effect on bone remodelling and a similar MRONJ risk profile at osteoporosis doses. Critically: do not stop denosumab without your doctor's guidance. Missing a dose without a transition plan can cause rapid bone loss and vertebral fractures.
Not routinely. AAOMS 2022 no longer recommends drug holidays as standard practice for low-risk patients. For oral osteoporosis doses, a brief pause provides little clinical benefit and slightly increases your fracture risk. Your dentist and physician will decide together if any modification is warranted in your specific case.
MRONJ typically presents as exposed bone in the mouth that does not heal within eight weeks — sometimes with pain, swelling, or an unusual taste. If you notice bone visible in the gum tissue after an extraction, particularly if it persists beyond two months, contact your dentist promptly. Early referral to an oral and maxillofacial surgeon improves outcomes.
Implants require individual assessment. For patients on oral osteoporosis doses without other risk factors, implants are generally possible, though the risk profile is slightly higher than for simple extraction. For patients on IV oncology-dose antiresorptives, implant placement is generally avoided. Your dentist will advise based on your specific drug, duration, and health history.
Yes. Routine dentistry — fillings, crowns, root canal treatment, periodontal cleaning, and check-ups — is appropriate for patients on osteoporosis-dose bisphosphonates. Elevated caution applies to procedures involving the bone: extraction, implant placement, and elective jaw surgery.
Yes — and the sooner the better. For what dental clearance before bisphosphonate therapy involves, see our dedicated guide: Bisphosphonate therapy and dental clearance in Singapore.
Tanjong Pagar · Singapore CBD
Book a consultation
For assessment before or during bisphosphonate therapy. We review your medication history, assess the tooth, and plan the safest approach. Oncology coordination available for complex cases.
52 Craig Rd, Tanjong Pagar · Mon–Fri 9am–6pm · Sat 9am–1pm
Clinical Sources
References
Clinical data and guideline recommendations cited in this guide are drawn from the following primary sources.
- Chua E et al. — Dental care for patients receiving antiresorptive agents: a modified Delphi consensus. BMC Oral Health, 2025;25:1706. Singapore-specific NUCOH/NUS multidisciplinary consensus — 29 clinical statements across 7 domains.
- Chan BH et al. — Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management. Singapore Med J, 2018;59(2):70–76. Singapore-specific CME guideline with local incidence context and road traffic injury risk comparison.
- American Association of Oral and Maxillofacial Surgeons — AAOMS Position Paper on Medication-Related Osteonecrosis of the Jaw: 2022 Update. J Oral Maxillofac Surg, 2022. Current diagnostic criteria, MRONJ staging (used in this guide), risk stratification, and updated drug holiday position.
- Beth-Tasdogan NH et al. — Interventions for managing osteonecrosis of the jaw. Cochrane Database Syst Rev, 2022. Primary systematic review underpinning the drug holiday evidence position cited in this guide.
- Agency for Care Effectiveness (ACE) — Osteoporosis: Recognising, Assessing and Managing the Risk of Fractures. MOH Singapore, 2025 Update. Singapore MOH-linked guideline on antiresorptive prescribing.
Medically Reviewed by
Principal Dentist and Founder · BDS (NUS) · SDC Reg. D21395J · 25+ Years of Clinical Experience · 10,000+ patients
This guide references the NUCOH Modified-Delphi Consensus 2025, AAOMS 2022 Position Paper, Cochrane Review 2022, Singapore Medical Journal CME 2018, and ACE Osteoporosis Guideline 2025. Last reviewed: August 2026. Next scheduled review: February 2027.
Dentalis is a MediSave-accredited and CHAS-accredited private dental clinic at 52 Craig Rd, Tanjong Pagar, Singapore 089690 — accessible from Maxwell MRT (Thomson-East Coast Line, Exit 3), Tanjong Pagar MRT (EW15), and Outram Park MRT (EW16/NE3/TE17). Recipient of three global awards in 2026. Rated 5.0 from 141 Google reviews.
This guide is for informational purposes and does not constitute clinical advice. Individual risk profiles vary — consult your dentist and prescribing physician before making any decisions about dental treatment or medication changes.